Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28526142 | 0.96 | ALDH1A1 (0.47) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20703549 | 0.93 | TDP1 (0.42) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20703719 | 0.92 | MAPT (0.41) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL9606830 | 0.89 | ALDH1A1 (0.40) | MAPTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3223924 | 0.88 | TDP1 (0.44) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5676255 | 0.88 | TDP1 (0.44) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1201863 | 0.86 | AKR1C3 (0.46) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3726022 | 0.86 | TSHR (0.49) | TDP1MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13014975 | 0.84 | MAPT (0.43) | TDP1ATMMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23412686 | 0.83 | KMT2A (0.41) | TDP1ATMMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| EP-1979316-B1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-07-11 | — | — | EP | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20100273853-A1 | NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2010-10-28 | — | — | US | disclosed |
| US-20100273853-A1 | NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2010-10-28 | — | — | US | disclosed |
| CN-101415678-A | Benzo (F) isoindol-2-ylphenylacetic acid derivatives as EP4Receptor agonists | GLAXO GROUP LTD (GB) | 2009-04-22 | — | — | CN | disclosed |
| WO-2009019281-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008020055-A1 | NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007088190-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | TDP1 4243/4885ATM 3475/4885MAPT 4512/4885 |
| US-20100273853-A1 | NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER3 | TDP1 3805/4885ATM 2861/4885MAPT 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.